Mahwah, NJ, United States of America

Sheng-Ding Fang


Average Co-Inventor Count = 5.9

ph-index = 3

Forward Citations = 24(Granted Patents)


Company Filing History:


Years Active: 1999-2004

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations of Sheng-Ding Fang

Introduction

Sheng-Ding Fang is a notable inventor based in Mahwah, NJ (US). He has made significant contributions to the field of science and technology, holding a total of four patents. His work primarily focuses on reversing advanced glycosylation end products, which have implications for both industrial and therapeutic applications.

Latest Patents

One of Sheng-Ding Fang's latest patents is titled "Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium compounds." This invention relates to compositions and methods aimed at reversing advanced glycosylation end product-mediated cross-linking and protein aging. The compositions described include thiazolium compounds substituted with heterocyclic groups that can reverse the formation of advanced glycosylation end product cross-links. The patent highlights both industrial and therapeutic applications, addressing issues such as food spoilage and animal protein aging. These compounds are particularly relevant in treating protein aging, which is associated with complications of aging and diabetes.

Career Highlights

Throughout his career, Sheng-Ding Fang has worked with various companies, including Alteon Incorporated. His innovative work has positioned him as a key figure in the field of glycosylation research.

Collaborations

Sheng-Ding Fang has collaborated with notable professionals in his field, including Dilip R Wagle and Taikyun Rho. These collaborations have contributed to the advancement of his research and inventions.

Conclusion

Sheng-Ding Fang's contributions to the field of glycosylation and protein aging are significant, showcasing his innovative spirit and dedication to scientific advancement. His patents reflect a commitment to addressing critical issues in both industrial and therapeutic contexts.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…